Abstract

Paenibacilli are efficient producers of potent agents against bacterial and fungal pathogens, which are of great interest both for therapeutic applications in medicine as well as in agrobiotechnology. Lipopeptides produced by such organisms play a major role in their potential to inactivate pathogens. In this work we investigated two lipopeptide complexes, the fusaricidins and the polymyxins, produced by Paenibacillus polymyxa strains DSM 32871 and M1 by MALDI-TOF mass spectrometry. The fusaricidins show potent antifungal activities and are distinguished by an unusual variability. For strain DSM 32871 we identified numerous yet unknown variants mass spectrometrically. DSM 32871 produces polymyxins of type E (colistins), while M1 forms polymyxins P. For both strains, novel but not yet completely characterized polymyxin species were detected, which possibly are glycosylated. These compounds may be of interest therapeutically, because polymyxins have gained increasing attention as last-resort antibiotics against multiresistant pathogenic Gram-negative bacteria. In addition, the volatilomes of DSM 32781 and M1 were investigated with a GC–MS approach using different cultivation media. Production of volatile organic compounds (VOCs) was strain and medium dependent. In particular, strain M1 manifested as an efficient VOC-producer that exhibited formation of 25 volatiles in total. A characteristic feature of Paenibacilli is the formation of volatile pyrazine derivatives.

Highlights

  • Paenibacillus spp. are distinguished by a large arsenal of bioactive secondary metabolites, such as nonribosomally formed lipopeptides, lassopeptides, polyketides, lantibiotics and bacteriocines, which are of high importance both in agrobiotechnology and medicine [1,2,3,4]

  • In this work we investigated the fusaricidin and polymyxin complexes produced by P. polymyxa DSM 32871 in comparison to those formed by the well-characterized strain M1 as model organism

  • In this work we investigated the biosynthetic potential of the Paenibacillus polymyxa strain DSM 32871

Read more

Summary

Introduction

Paenibacillus spp. are distinguished by a large arsenal of bioactive secondary metabolites, such as nonribosomally formed lipopeptides, lassopeptides, polyketides, lantibiotics and bacteriocines, which are of high importance both in agrobiotechnology and medicine [1,2,3,4] They are efficient producers of potent agents against both bacterial and fungal pathogens. The most abundant bioactive compounds of these organisms are lipopeptides, which cover a broad range of structurally diverse linear and cyclic species with peptide chain lengths between 6 and 13 amino acids and manifold variations in their fatty acid chains. They comprise fusaricidins and the related LiF-antibiotics The exploitation of the bioactive agents produced by P. polymyxa may contribute to solve this insistent public health issue

Methods
Results
Conclusion
Full Text
Published version (Free)

Talk to us

Join us for a 30 min session where you can share your feedback and ask us any queries you have

Schedule a call